P093: From involved- field to involved-node – Quality analysis of the radiation therapy in HD 17 by the expert panel of the German Hodgkin Study Group
Main Authors: | Michael Oertel, Dominik Hering, Nina Nacke, Christopher Kittel, Kai Kröger, Jan Kriz, Michael Fuchs, Christian Baues, Dirk Vordermark, Rita Engenhart-Cabillic, Klaus Herfarth, Peter Lukas, Heinz Schmidberger, Simone Marnitz, Peter Borchmann, Andreas Engert, Uwe Haverkamp, Hans Theodor Eich |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-10-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000890940.13779.4a |
Similar Items
-
P092: Estimating the dosimetric benefit of involved-node radiotherapy in comparison to involved-field radiotherapy - implications from the GHSG HD 17 trial
by: Michael Oertel, et al.
Published: (2022-10-01) -
P097: The status quo of involved-field radiotherapy – Quality analysis of radiotherapy in the GHSG HD 16
by: Michael Oertel, et al.
Published: (2022-10-01) -
Radiation doses to mediastinal organs at risk in early-stage unfavorable Hodgkin lymphoma– a risk stratified analysis of the GHSG HD17 trial
by: Michael Oertel, et al.
Published: (2023-05-01) -
Radiation Therapy in the German Hodgkin Study Group HD 16 and HD 17 Trials: Quality Assurance and Dosimetric Analysis for Hodgkin Lymphoma in the Modern Era
by: Michael Oertel, MD, et al.
Published: (2023-05-01) -
Estimation of Mediastinal Toxicities after Radiotherapy for Hodgkin Lymphoma—A Normal Tissue Complication Analysis of the HD16/17 Trial by the German Hodgkin Study Group
by: Michael Oertel, et al.
Published: (2024-03-01)